These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

994 related articles for article (PubMed ID: 21741088)

  • 1. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS; Markowitz J; Wyllie R
    J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
    N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
    Baldassano R; Braegger CP; Escher JC; DeWoody K; Hendricks DF; Keenan GF; Winter HS
    Am J Gastroenterol; 2003 Apr; 98(4):833-8. PubMed ID: 12738464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.
    Dotan I; Ron Y; Yanai H; Becker S; Fishman S; Yahav L; Ben Yehoyada M; Mould DR
    Inflamm Bowel Dis; 2014 Dec; 20(12):2247-59. PubMed ID: 25358062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
    Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
    Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
    Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.
    Ternant D; Mulleman D; Degenne D; Willot S; Guillaumin JM; Watier H; Goupille P; Paintaud G
    Ther Drug Monit; 2006 Apr; 28(2):169-74. PubMed ID: 16628126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
    Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP
    Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.